Breaking News

Innovative Technology Enables Ultrasensitive Detection of HPV-related Cancer

December 20, 2020 • 11:00 am CST
(Vax Before Cancer)

Piyush B. Gupta, Ph.D., Founder & Chief Executive Officer said in a press statement, “The best approach to eliminating the morbidity and mortality from cancer is to implement innovative technologies, accessible to treating physicians and patients, that demonstrate a significant improvement in early-stage diagnosis when treatment can be curative. This core belief serves as the guiding principle for all of our activities at Naveris, in order to transform the lives of patients suffering from virus-related cancers."

Naveris’ lead product, NavDx®, applies proprietary technology to enable ultrasensitive detection of HPV-related cancer and has been clinically validated through a 3-year longitudinal study, demonstrating 100% negative predictive value and 94% positive predictive value in detecting the recurrence of HPV-related head and neck cancer.

The findings, published in the Journal of Clinical Oncology, were from the largest and most comprehensive study investigating a blood test in HPV-related head and neck cancer. Naveris currently provides the NavDx test through its CLIA laboratory to cancer centers throughout the USA.